These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 146706)

  • 1. Studies on human urinary enzymes and inhibitors. Concentration method and characterization.
    Sumi H; Toki N; Takada Y; Takada A
    J Biochem; 1978 Jan; 83(1):141-7. PubMed ID: 146706
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of subpopulations of human urinary plasminogen activators.
    Hart DA; Kramer R; Cieplak W
    Thromb Haemost; 1984 Apr; 51(2):212-6. PubMed ID: 6539958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International committee communications. Report of the subgroup on fibrinolytic inhibitors, subcommittee on fibrinolysis.
    Hedner U
    Thromb Haemost; 1979 May; 41(3):622-4. PubMed ID: 37610
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrinolytic inhibitors in human seminal plasma.
    Liedholm P; Astedt B
    Experientia; 1974 Oct; 30(10):1113-4. PubMed ID: 4279828
    [No Abstract]   [Full Text] [Related]  

  • 6. Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.
    Turpeinen U; Koivunen E; Stenman UH
    Biochem J; 1988 Sep; 254(3):911-4. PubMed ID: 2461702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of polypeptide backbone structure as determined by circular dichroic spectral analysis in relation to change of plasminogen activator activity of two forms of human urinary urokinase denatured with guanidine hydrochloride.
    Miwa N; Yamashita A; Suzuki A
    Chem Pharm Bull (Tokyo); 1982 Oct; 30(10):3669-78. PubMed ID: 6761000
    [No Abstract]   [Full Text] [Related]  

  • 8. [Selected problems from the enzymatic diagnosis of urinary tract diseases in children].
    Zaniewska J; Skôrowa J; Zaniewski A
    Wiad Lek; 1978 Nov; 31(22):1613-6. PubMed ID: 366910
    [No Abstract]   [Full Text] [Related]  

  • 9. Isolation of a plasminogen activator (urokinase) from urine.
    PLOUG J; KJELDGAARD NO
    Arch Biochem Biophys; 1956 Jun; 62(2):500-1. PubMed ID: 13328139
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
    Gurewich V; Pannell R
    Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
    [No Abstract]   [Full Text] [Related]  

  • 11. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketone.
    Kettner C; Shaw E
    Methods Enzymol; 1981; 80 Pt C():826-42. PubMed ID: 6210829
    [No Abstract]   [Full Text] [Related]  

  • 12. Monoclonal antibodies against human high molecular weight urinary urokinase: application for affinity purification of urinary prourokinase.
    Wojta J; Kirchheimer JC; Turcu L; Christ G; Binder BR
    Thromb Haemost; 1986 Jun; 55(3):347-51. PubMed ID: 3092391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading].
    Dovgan' AA
    Lik Sprava; 1992 Aug; (8):39-41. PubMed ID: 1475923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of urinary enzyme determinations.
    Raab WP
    Clin Chem; 1972 Jan; 18(1):5-25. PubMed ID: 4332365
    [No Abstract]   [Full Text] [Related]  

  • 16. Estimation of the plasminogen activator and the trypsin inhibitor in animal and human tissues.
    ASTRUP T; ALBRECHTSEN OK
    Scand J Clin Lab Invest; 1957; 9(3):233-43. PubMed ID: 13495339
    [No Abstract]   [Full Text] [Related]  

  • 17. Formation of stable complexes between urokinase and a human urinary component.
    Cieplak W; Hart DA
    Thromb Haemost; 1985 Feb; 53(1):36-41. PubMed ID: 4039474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of netropsin and pentamidine amino analogues on the amidolytic activity of plasmin, trypsin and urokinase.
    Pućkowska A; Midura-Nowaczek K; Bruzgo I
    Acta Pol Pharm; 2008; 65(2):213-5. PubMed ID: 18666427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
    Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
    Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.